#3839 THERAPEUTIC TARGETS OF ARSENIC TRIOXIDE IN LUPUS NEPHRITIS – DATA FROM BIOINFORMATICS ANALYSIS AND IN VITRO STUDIES

Abstract Background and Aims Patients with systemic lupus erythematosus (SLE) are at an increased risk of developing nephritis (LN), which results in high morbidity mortality. There is preliminary data showing the efficacy low dose Arsenic Trioxide (ATO) reducing renal flares amongst LN patients, but underlying mechanism for such benefit remains unclear. Method We performed bioinformatic analysis network pharmacology to elucidate potential targets from differentially expressed genes (DEGs) human SLE peripheral blood mononuclear cells (PBMCs) datasets pharmacological databases. The relationship between immune was further analyzed. Results Twelve intersection DEGs SLE, predicting ATO related were identified. KEGG pathway suggested that mechanisms associated IL-17 signalling (p = 1.67E-18), TNF 5.77E-11) NOD-like receptor 1.93E-09). Ten types showed significant difference expression using ssGSEA approach. MMP9 most significantly positive correlations macrophages neutrophils. A TF-MMP9-miRNA regulatory constructed cytoscape software. Pilot our vitro studies might downregulate PBMCs obtained patients during disease remission (n 3). Conclusion interacts via different inflammatory pathways may PBMCs.